Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol

BACKGROUND: Despite multimodality treatments including neurosurgery, radiotherapy and chemotherapy, glioblastoma (GBM) prognosis remains poor. GBM is classically considered as a radioresistant tumor, because of its high local recurrence rate, inside the irradiation field. The development of new radi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lesueur, Paul, Lequesne, Justine, Grellard, Jean-Michel, Dugué, Audrey, Coquan, Elodie, Brachet, Pierre-Emmanuel, Geffrelot, Julien, Kao, William, Emery, Evelyne, Berro, David Hassanein, Castera, Laurent, Goardon, Nicolas, Lacroix, Joëlle, Lange, Marie, Capel, Aurélie, Leconte, Alexandra, Andre, Benoit, Léger, Angélique, Lelaidier, Anaïs, Clarisse, Bénédicte, Stefan, Dinu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399862/
https://www.ncbi.nlm.nih.gov/pubmed/30832617
http://dx.doi.org/10.1186/s12885-019-5413-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399862/
https://www.ncbi.nlm.nih.gov/pubmed/30832617
http://dx.doi.org/10.1186/s12885-019-5413-y

Ejemplares similares